comparemela.com
Home
Live Updates
New England Retina Consultants - Breaking News
Pages:
2
3
4
5
6
7
8
Latest Breaking News On - New england retina consultants - Page 1 : comparemela.com
Keeping A Watchful Eye: Safety Reports in Geographic Atrophy Landscape
A headline year for retina disease drug development concurrently brought about research and discussion into the safety outcomes of these new agents.
United states
San francisco
Iapocec apellis
David lally
Kunzmannk apellis
Dilsher dhoot
Veeral sheth
Iapocec charles wykoff
Charles wykoff
Nathan steinle
Avacincaptad pegol
Iapocec pegcetacoplan
Iapocec nathan steinle
University retina
Apellis pharmaceuticals
Macula associates
David Lally, MD: Perspective on ANX007 for Geographic Atrophy
At AAO 2023, David Lally, MD describes results from the phase 2 ARCHER study and the potential benefit of intravitreal ANX007 for patients with GA.
United states
San francisco
David lally
American academy of ophthalmology
Annual american academy
Retina research institute
New england retina consultants
Neuroprotective Agent Prevents Significant Vision Loss in Geographic Atrophy
Consistent vision effect with complement C1q inhibitor, despite no effect on lesion size
United states
Charles bankhead
Los angeles
David lally
Mark humayun
Subers huang
Retina center
American academy of ophthalmology
University of southern california
New england retina consultants
American academy
Southern california
Medpage today
Retinal late breaking
ANX007 is a Potential Treatment for Geographic Atrophy, According to ARCHER Study
ARCHER study demonstrated that the antibody ANX007 was time and dose dependent, robust, and not dependent on lesion growth.
United states
San francisco
David lally
American academy of ophthalmology
New england
New england retina consultants
Geographic atrophy secondary
Age related macular degeneration
Selective classical complement inhibitor
Annual american academy
David Lally, MD: Efficacy of Oral APX3330 for Diabetic Retinopathy
Presented at ASRS 2023, results from the phase 2 ZETA-1 trial showed oral APX3330 missed its primary endpoint, but the consideration of a binocular treatment effect may warrant further clinical development.
United states
David lally
American society of retina specialists
American society
Retina specialists
Annual meeting
Retina research institute
New england retina consultants
vimarsana © 2020. All Rights Reserved.